EGR1 Targeting Molecules for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional treatments for inflammation do not fundamentally cure the condition and are often associated with side effects such as hypersensitivity reactions and deterioration of the immune system, with chronic inflammatory diseases like psoriasis lacking a cure.
Innovation Solution
Development of compounds that induce SAMD9 transcriptional activity to down-regulate EGR1 expression, which are used to treat inflammatory and hyperproliferative diseases, including psoriasis, by administering therapeutically effective amounts of specific compounds represented by Formulas I, II, or III.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for inflammation are used, then inflammation is suppressed, but side effects such as hypersensitivity reactions and deterioration of the immune system occur
Solution Approach 1:
The patent extracts and targets a specific molecular pathway (EGR1) that drives inflammation and hyperproliferation, separating the therapeutic action from non-specific immune suppression. By directly inhibiting EGR1 expression through SAMD9 activation, the treatment achieves anti-inflammatory effects without the harmful side effects of conventional broad-spectrum immunosuppressants
Solution Approach 2:
The patent introduces SAMD9 as an intermediary protein that mediates the therapeutic effect. Activating SAMD9 expression leads to downregulation of EGR1, which in turn reduces inflammation and hyperproliferation. This intermediary mechanism allows for targeted therapy that avoids direct suppression of the immune system, thereby eliminating hypersensitivity reactions and immune deterioration
2Reliability
If conventional treatments for chronic inflammatory diseases like psoriasis are used, then symptoms are managed, but the condition cannot be cured
Solution Approach 1:
Instead of suppressing inflammation through conventional immunosuppressive approaches, the patent inverts the strategy by activating a specific regulator (SAMD9) that naturally inhibits the inflammatory pathway (EGR1). This inverse approach targets the root cause of the disease mechanism rather than merely managing symptoms, enabling potential cure rather than lifelong management
Solution Approach 2:
The patent changes the regulatory parameter of EGR1 expression from high (pathological state) to low (healthy state) by activating SAMD9. This parameter change in gene expression levels fundamentally alters the disease state, transforming chronic inflammatory conditions into remission and enabling cure rather than temporary symptom management
3Reliability
If EGR1 expression is downregulated through SAMD9 activation, then inflammatory and hyperproliferative conditions are treated, but the mechanism is complex
Solution Approach 1:
The patent segments the complex molecular mechanism into two distinct functional components: SAMD9 activation (therapeutic action) and EGR1 downregulation (mechanistic outcome). This segmentation simplifies the understanding and treatment approach by focusing on activating one protein to achieve the desired effect of reducing another, making the complex biological pathway manageable and targetable
Data Source
AI summary
A method of treating an inflammation or a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:a compound represented by Formula I:or a pharmaceutically acceptable salt thereof,a compound represented by Formula II:and a compound represented by Formula III:wherein the variables in Formulae I, II and III are as defined in the specification.